Mayo Clinic Laboratories now offers a comprehensive addiction rehabilitation monitoring profile, an innovative assay that employs a combination of technologies to test urine for the most commonly used substances. In this test specific episode of the "Answers From the Lab" podcast, Loralie Langman, Ph.D., and Paul Jannetto, Ph.D., discuss the test’s utility to help guide and monitor treatment.

“Urine drug testing has been referred to as the technology of addiction treatment,” Dr. Jannetto says. “It’s not meant to be punitive, but rather as a tool to support recovery and provide motivation or reinforcement for abstinence.”

Developed for clinicians who manage complex patients struggling with substance use disorders to common substances such as opioids, marijuana, alcohol, and nicotine, the addiction monitoring profile offers improved specificity and includes adulterant testing and enhanced reports. Listen to learn more about how our testing enables accurate answers and simplified results to clarify patients’ substance use.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ADMPU | Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

Useful information

• Assessing patients at-risk for substance use disorders.
• Detecting drug use involving stimulants, barbiturates, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, alcohol, and nicotine.
• This test is not intended for use in employment-related testing.

Specimen requirements

Specimen Type: Urine Container, 60 mL (T313)

Specimen Volume: 30 mL

Container/Tube: Plastic urine container

Collection Instructions:

• Collect a random urine specimen.
• Submit 30 mL in 1 plastic bottle.
• No preservative.

Additional Information:

• No specimen substitutions.
• Submitting less than 30 mL may compromise the ability to perform all necessary testing.
• STATS are not accepted for this procedure.

Performance information

Analytic time: 2 to 5 days 

Days performed: Varies

The latest

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

Noninvasive plasma biomarker testing provides faster answers: Alicia Algeciras-Schimnich, Ph.D. 

April 9, 2024

Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.

View MoreView Less